News
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE ...
San Diego’s once-sizzling biotech scene is now in a cold snap. It’s left some workers desperate after months of fruitless job ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...
InvestorsHub on MSN22h
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light
Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the ...
The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...
Stockhead on MSN10h
Health Check: Audeara strives to be ‘the next Cochlear’ in affordable hearing collab
Cochlear’s Baha devices – as in bone-anchored hearing aid – cost around $10,000 locally. Strictly speaking, the $4 million ...
Researchers have found that common viruses, like covid and the flu, can reactivate dormant breast cancer cells. In other news: Johnson & Johnson launches "The 3rd Opinion" initiative to empower ...
Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 falling 1.25%, Hong Kong's Hang Seng gaining 0.92%, ...
Investor's Business Daily on MSN16h
IBD 50's Hims & Hers Plummets 9% On Second-Quarter Sales Miss
The company reiterated its sales outlook for the year, despite coming in with lighter-than-expected second-quarter sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback